• Cross-sex HT not associated with surgical risk in transgender adults

    5 monthes ago - By Healio

    There is “insufficient evidence” to support the routine discontinuation of testosterone or spironolactone therapy in transgender patients who are undergoing scheduled surgical procedures, whereas inconsistent risk data regarding estrogen therapy suggests careful consideration about whether to stop before surgery, according to a systematic review published in JAMA Surgery.
    “There shouldn't be a one-size-fits-all approach for how surgeons handle medication management for gender-diverse patients in the perioperative period,” Elizabeth R. Boskey, PhD, social worker
    Read more ...